Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P30304

UPID:
MPIP1_HUMAN

ALTERNATIVE NAMES:
Dual specificity phosphatase Cdc25A

ALTERNATIVE UPACC:
P30304; Q8IZH5; Q96IL3; Q9H2F2

BACKGROUND:
The protein known as M-phase inducer phosphatase 1, or Dual specificity phosphatase Cdc25A, is integral to the progression of the mitotic phase of the cell cycle. It achieves this by dephosphorylating CDK1, thereby stimulating its kinase activity, and similarly affects CDK2 in the presence of cyclin E. This regulatory mechanism ensures the timely and orderly progression of cell division.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of M-phase inducer phosphatase 1 offers a promising avenue for developing novel therapeutic approaches. Given its central role in regulating the cell cycle, targeting this protein could yield breakthroughs in treating conditions marked by dysregulated cell growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.